Mississippi Funds Psychedelic Therapy Research | Hattiesburg News

Mississippi is pioneering a bold new approach to addiction and mental health by funding research into psychedelic therapies like ibogaine and psilocybin—using $5 million from opioid settlements to explore treatments that could transform recovery. Ibogaine, from an African plant, can disrupt opioid withdrawal but demands rigorous medical oversight due to cardiac risks; psilocybin, from magic mushrooms, shows promise for depression and PTSD by restoring brain connectivity. Both require careful preparation, supportive environments, and follow-up care—not recreation. As states like Oregon and Colorado build regulated systems, Mississippi’s move could soon offer residents local access to these breakthroughs, potentially reducing long-term costs and shifting focus from punishment to healing. Insurance coverage remains a hurdle, but the potential for lasting, personalized recovery is driving this evolving public health strategy. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8b6e3158e3c150bc